Evidence map›Paper›PMID 37572120›Full record

ArticleJournal of cancer research and clinical oncology2023

Exploring the correlation between HER2 alterations and

Maomei Ruan, Cheng Chang, Jianwen Sun, Liu Liu, Lihua Wang, Bei Lei, Hui Yan, He Zhang, Wenhui Xie, Yuetao Wang

Open access · greenAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of cancer research and clinical oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Prognostic value of baseline [68Ga]Ga‑DOTA‑NOC PET/CT in paediatric neuroblastoma.European journal of nuclear medicine and molecular imaging · 2026
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Maomei Ruan *Department of Nuclear Medicine, The Third Affiliated Hospital of Soochow University, No. 185, Juqian Street, Changzhou, 213003, Jiangsu, People's Republic of China.
Cheng Chang *Department of Nuclear Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200030, People's Republic of China.
Jianwen Sun *Department of Nuclear Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200030, People's Republic of China.
Liu LiuDepartment of Nuclear Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200030, People's Republic of China.
Lihua WangDepartment of Nuclear Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200030, People's Republic of China.
Bei LeiDepartment of Nuclear Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200030, People's Republic of China.
Hui YanDepartment of Nuclear Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200030, People's Republic of China.
He ZhangDepartment of Nuclear Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200030, People's Republic of China.
Wenhui Xie *Department of Nuclear Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, 200030, People's Republic of China.
Yuetao Wang *Department of Nuclear Medicine, The Third Affiliated Hospital of Soochow University, No. 185, Juqian Street, Changzhou, 213003, Jiangsu, People's Republic of China. yuetao-w@163.com.
Shanghai Jiao Tong University · CNShanghai Chest Hospital · CNSoochow University · CN

Funding

basic research of Shanghai Chest Hospital 2020YNJCM07basic research of Shanghai Chest Hospital 2020YNJCQ06basic research of Shanghai Chest Hospital 2020YNJCQ11basic research of Shanghai Chest Hospital 2021YNJCM09Key Laboratory of Changzhou High-tech Research Project CM20193010National Natural Science Foundation of China 81871381National Natural Science Foundation of China 82202219National Natural Science Foundation of China 82272044Natural Science Foundation of Shanghai 21ZR1458900Nurture projects for the special project of integrated traditional Chinese and Western medicine in general hospital of Shanghai Health Committee ZHYY-ZXYJHZX-202023Shanghai Sailing Program 20YF1444500Shanghai Sailing Program 21YF1442700Youth Medical Talents-Medical Imaging Practitioners Program SHWRS(2020)_087
6 · The paper itself

Abstract

purposeOur study intended to explore the correlation between HER2 alterations and

methodsNGS assay was performed in 1737 NSCLC patients, a total of 88 HER2 alterations and 176 negative HER2 with EGFR-negative patients were randomly selected for this study.

resultsWhen the HER2 status with EGFR-negative group was analyzed, multivariate analysis showed that smoking status, primary tumor SUVmax (pSUVmax) < 13.03 and stage were the independent deterministic factors of HER2 alterations. Multivariate cox regression analysis revealed that HER2 status, age, smoking status and stage were independent risk factors for overall survival (OS) in EGFR-negative NSCLC patients with different HER2 status. When the HER2 alterations group was separately analyzed, multivariate analysis demonstrated that low pSUVmax < 15.32 and histology were the independent deterministic factors of HER2 mutation. Multivariate cox regression analysis revealed that pSUVmax, smoking status, nodal involvement and treatment methods were independent risk factors for OS in EGFR-negative NSCLC patients with HER2 alterations.

conclusionThe study revealed that low pSUVmax was associated with HER2 alterations in EGFR-negative NSCLC patients, moreover HER2 mutation and HER2 amplification exhibited distinct

Indexed as

Carcinoma, Non-Small-Cell LungLung NeoplasmsErbB ReceptorsFluorodeoxyglucose F18HumansPositron Emission Tomography Computed TomographyPrognosisRetrospective StudiesEGFR protein, humanErbB ReceptorsFluorodeoxyglucose F18HER2 amplificationHER2 mutationNGSNon-small-cell lung cancerOverall survival

Identifiers

PMID37572120
PMCPMC11796604
OpenAlexW4385782895

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.